Cyclacel Pharmaceuticals (CYCC) Soars 91.11% on Dividend, Capital Boost

On April 29, 2025, Cyclacel Pharmaceuticals, Inc. (CYCC) experienced a remarkable surge, with its stock price rising by 91.11% in pre-market trading. This significant increase can be attributed to several key developments that have captured the attention of investors.

One of the primary drivers behind this surge is the announcement of a stock dividend by Cyclacel Pharmaceuticals. The company declared a dividend of $0.15 per share, with the ex-date set for April 29, 2025. This dividend payout is expected to provide a boost to investor confidence and attract more buyers to the stock.

Additionally, Cyclacel Pharmaceuticals has been actively engaged in increasing its authorized share capital. The company filed a Certificate of Amendment to raise the number of authorized shares, which is a strategic move to support future growth and expansion. This initiative is likely to enhance the company's financial flexibility and attractiveness to potential investors.

Furthermore, the company's recent securities purchase agreement has also contributed to the positive market sentiment. This agreement, which involves the issuance of securities to raise capital, is seen as a proactive step towards funding the company's ongoing research and development efforts. Investors are optimistic about the potential breakthroughs that could result from these investments, driving up the stock price.